Parsifal Capital Management sold 4,239,655 shares of Albertsons Companies in the fourth quarter.
The quarter-end position value decreased by $75.08 million, reflecting both trading activity and stock price movements.
The post-trade stake stood at 2,469,593 shares valued at $42.40 million.
The stake now comprises 3.48% of AUM, which places it outside the fund's top five holdings.
On February 17, 2026, Parsifal Capital Management disclosed a sale of 4,239,655 shares of Albertsons Companies (NYSE:ACI), with an estimated transaction value of $75.60 million based on quarterly average pricing.
According to a February 17, 2026, SEC filing, Parsifal Capital Management reduced its position in Albertsons Companies by 4,239,655 shares. The estimated transaction value is $75.60 million, calculated using the average unadjusted closing price during the fourth quarter of 2025. The quarter-end value of the stake dropped by $75.08 million, a change that includes both the share sale and the impact of price movements.
| Metric | Value |
|---|---|
| Revenue (TTM) | $81.72 billion |
| Net Income (TTM) | $870.00 million |
| Dividend Yield | 3.27% |
| Price (as of market close 2/17/26) | $18.47 |
Albertsons Companies, Inc. is one of the largest food and drug retailers in the United States, operating thousands of stores under multiple regional banners. The company's vertically integrated business model, including in-house food manufacturing and distribution, supports its scale and efficiency. Its broad store footprint and diverse product offerings position Albertsons as a key player in the competitive grocery sector.
Trimming Albertsons from roughly 10.9% of assets to just 3.5% meaningfully reduces exposure to a defensive grocery operator, but frees up capital for higher growth or more idiosyncratic bets. That stands out in a portfolio now led by names like SharkNinja, Hilton Grand Vacations, Globus Medical, Teva, and GXO, which skew toward consumer products, healthcare, and logistics rather than low-margin food retail.
Operationally, Albertsons remains steady. Third quarter net sales rose 1.9% to $19.1 billion, identical sales increased 2.4%, and digital sales jumped a very notable 21%. The company also reiterated full-year identical sales growth of 2.2% to 2.5%.
Shares, nonetheless, are down 7.7% over the past year, trailing the broader market. For long term investors, the appeal is cash flow durability and scale across more than 2,200 stores. But with margins under pressure from pharmacy mix and digital fulfillment costs, this looks like a portfolio shift away from steady compounding toward opportunities with greater upside torque, and not necessarily a broken story that can’t be fixed.
Before you buy stock in Albertsons Companies, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Albertsons Companies wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $415,256!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,151,865!*
Now, it’s worth noting Stock Advisor’s total average return is 892% — a market-crushing outperformance compared to 194% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of February 20, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Globus Medical and SharkNinja. The Motley Fool recommends GXO Logistics. The Motley Fool has a disclosure policy.